News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
386,691 Results
Type
Article (25245)
Company Profile (32)
Press Release (361412)
Multimedia
Podcasts (120)
Webinars (14)
Section
Business (122214)
Career Advice (1468)
Deals (17786)
Drug Delivery (78)
Drug Development (43837)
Employer Resources (100)
FDA (9012)
Job Trends (8707)
News (195351)
Policy (17681)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (1495)
Academic (1)
Accelerated approval (16)
Adcomms (15)
Allergies (86)
Alliances (33811)
ALS (106)
Alzheimer's disease (1011)
Antibody-drug conjugate (ADC) (221)
Approvals (9245)
Artificial intelligence (348)
Autoimmune disease (96)
Automation (27)
Bankruptcy (161)
Best Places to Work (7190)
BIOSECURE Act (12)
Biosimilars (113)
Biotechnology (26)
Bladder cancer (120)
Brain cancer (37)
Breast cancer (428)
Cancer (3312)
Cardiovascular disease (279)
Career advice (1266)
Career pathing (30)
CAR-T (147)
CDC (31)
Cell therapy (467)
Cervical cancer (26)
Clinical research (37823)
Collaboration (1307)
Company closure (2)
Compensation (285)
Complete response letters (28)
COVID-19 (1594)
CRISPR (62)
C-suite (460)
Cystic fibrosis (85)
Data (4313)
Decentralized trials (2)
Denatured (40)
Depression (83)
Diabetes (340)
Diagnostics (3628)
Digital health (26)
Diversity (7)
Diversity, equity & inclusion (30)
Drug discovery (172)
Drug pricing (123)
Drug shortages (21)
Duchenne muscular dystrophy (147)
Earnings (58340)
Editorial (44)
Employer branding (14)
Employer resources (88)
Events (58017)
Executive appointments (562)
FDA (11043)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (5)
Frontotemporal dementia (17)
Funding (845)
Gene editing (128)
Generative AI (39)
Gene therapy (406)
GLP-1 (616)
Government (2540)
Grass and pollen (6)
Guidances (324)
Healthcare (10361)
HIV (44)
Huntington's disease (29)
IgA nephropathy (57)
Immunology and inflammation (154)
Immuno-oncology (42)
Indications (81)
Infectious disease (1745)
Inflammatory bowel disease (126)
Inflation Reduction Act (14)
Influenza (61)
Intellectual property (154)
Interviews (272)
IPO (8499)
IRA (36)
Job creations (1835)
Job search strategy (1028)
JPM (44)
Kidney cancer (11)
Labor market (53)
Layoffs (298)
Leadership (29)
Legal (4522)
Liver cancer (50)
Longevity (10)
Lung cancer (473)
Lymphoma (269)
Machine learning (24)
Management (34)
Manufacturing (514)
MASH (122)
Medical device (6871)
Medtech (6902)
Mergers & acquisitions (9986)
Metabolic disorders (835)
Multiple sclerosis (114)
NASH (9)
Neurodegenerative disease (189)
Neuropsychiatric disorders (51)
Neuroscience (1765)
NextGen: Class of 2026 (3482)
Non-profit (2727)
Now hiring (8)
Obesity (365)
Opinion (210)
Ovarian cancer (97)
Pain (118)
Pancreatic cancer (138)
Parkinson's disease (165)
Partnered (21)
Patents (288)
Patient recruitment (245)
Peanut (28)
People (29811)
Pharmaceutical (10)
Pharmacy benefit managers (16)
Phase 1 (11369)
Phase 2 (16147)
Phase 3 (13553)
Pipeline (3855)
Policy (192)
Postmarket research (1690)
Preclinical (4904)
Press Release (31)
Prostate cancer (201)
Psychedelics (29)
Radiopharmaceuticals (174)
Rare diseases (538)
Real estate (2660)
Recruiting (39)
Regulatory (13283)
Reports (25)
Research institute (1399)
Resumes & cover letters (222)
Rett syndrome (19)
RNA editing (10)
RSV (49)
Schizophrenia (95)
Series A (147)
Series B (96)
Service/supplier (3)
Sickle cell disease (68)
Special edition (15)
Spinal muscular atrophy (77)
Sponsored (27)
Startups (1623)
State (1)
Stomach cancer (14)
Supply chain (60)
Tariffs (53)
The Weekly (78)
Vaccines (663)
Venture capital (53)
Weight loss (229)
Women's health (51)
Worklife (16)
Date
Last 7 days (357)
Last 30 days (1285)
Last 365 days (19150)
2026 (1806)
2025 (19357)
2024 (20667)
2023 (22753)
2022 (29304)
2021 (31033)
2020 (30170)
2019 (25778)
2018 (19046)
2017 (18059)
2016 (17473)
2015 (19906)
2014 (16595)
2013 (14521)
2012 (14385)
2011 (13849)
2010 (13074)
Location
Africa (574)
Alabama (60)
Alaska (5)
Arizona (128)
Arkansas (7)
Asia (22595)
Australia (3804)
California (6580)
Canada (1987)
China (700)
Colorado (309)
Connecticut (330)
Delaware (212)
Europe (53625)
Florida (1105)
Georgia (224)
Hawaii (1)
Idaho (23)
Illinois (490)
India (44)
Indiana (360)
Iowa (10)
Japan (305)
Kansas (73)
Kentucky (17)
Louisiana (8)
Maine (31)
Maryland (828)
Massachusetts (4875)
Michigan (196)
Minnesota (295)
Mississippi (2)
Missouri (54)
Montana (11)
Nebraska (9)
Nevada (77)
New Hampshire (35)
New Jersey (2143)
New Mexico (13)
New York (1890)
North Carolina (888)
North Dakota (5)
Northern California (3167)
Ohio (169)
Oklahoma (14)
Oregon (21)
Pennsylvania (1429)
Puerto Rico (7)
Rhode Island (27)
South America (778)
South Carolina (31)
Southern California (2660)
Tennessee (119)
Texas (1023)
United States (24245)
Utah (218)
Vermont (1)
Virginia (146)
Washington D.C. (56)
Washington State (552)
West Virginia (3)
Wisconsin (62)
Wyoming (2)
386,691 Results for "merck sharp and dohme".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Merck Bats Away ‘Modest Growth’ Accusations, Touts Broad Pipeline
In its 2025 full year and fourth-quarter earnings call, Merck executives touted the merits of recent deals and what CEO Robert Davis called “probably the broadest and widest pipeline we’ve had in years.”
February 3, 2026
·
2 min read
·
Dan Samorodnitsky
Mergers & acquisitions
Merck Backs Off Revolution After Failing To Agree on Price: WSJ
Merck had previously offered anywhere from $28 billion to $32 billion to swallow Revolution Medicines.
January 26, 2026
·
1 min read
·
Tristan Manalac
Mergers & acquisitions
Revolution Knows Its Worth as Merck Backs Off—For Now
Investors are apparently taking bets on when Revolution will be acquired. A handful of pharmas could be interested as Merck backs off.
January 26, 2026
·
4 min read
·
Annalee Armstrong
Ovarian cancer
Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie
Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities said Thursday.
January 26, 2026
·
2 min read
·
Tristan Manalac
Events
JPM26: Confident Merck Sees Growth Through Keytruda Loss of Exclusivity
Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Monday, revealing that the company is open to deals in the range of “multi tens of billions of dollars.”
January 13, 2026
·
1 min read
·
Heather McKenzie
Press Releases
Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants
February 5, 2026
·
6 min read
Press Releases
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary
January 5, 2026
·
4 min read
Press Releases
Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes
February 2, 2026
·
6 min read
Vaccines
As Kennedy Takes Aim at Childhood Vaccines, a History of Merck’s ProQuad
While last week’s recommended changes by CDC advisors to the MMRV vaccine schedule are unlikely to have a tangible effect on Merck’s business, the company said the removal of choice for healthcare providers is “concerning.”
September 23, 2025
·
6 min read
·
Annalee Armstrong
Cardiovascular disease
Merck Builds Case for Cholesterol-Lowering Pill With Injectable-Like Efficacy
Multiple analyst firms were impressed by the Phase III data, which showed that Merck’s oral PCSK9 inhibitor can lower low-density lipoprotein cholesterol by more than 55% after 24 weeks.
November 10, 2025
·
2 min read
·
Tristan Manalac
1 of 38,670
Next
